Showing results (61-70 of 81) with videos related to
Sort By:
Pageof 9
Blood|October 22, 2010
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myelomaMoshe E Gatt, Jian-Jun Zhao, Margaret S Ebert, et al.Cell Death & Disease|November 18, 2022
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myelomaOdai Darawshi, Barbara Muz, Shiri Gershon Naamat, et al.International Journal of Molecular Sciences|April 14, 2026
Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell TherapyIdo Cohen, Eyal Lebel, Sigal Grisariu, et al.Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.American Journal of Hematology|January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter studyDrorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL AmyloidosisEyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.Blood Advances|May 20, 2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myelomaShlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, et al.Pageof 9